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 “Educating your mind without educating your heart is no education at all”
          Aristotle
          To my family

5ABSTRACT
Background: Heart failure (HF) is a major health problem worldwide with exponentially increas-
ing incidence with age and the majority of patients being elderly. In recent years, an increase in 
hospitalization and prevalence of HF in younger persons has been documented in Sweden and 
Denmark, in contrast to an overall decrease in older patients. In addition, an increase in hospital 
discharge diagnoses of cardiomyopathy has been reported, also most pronounced among the 
young. New treatment modalities implemented in every day practice have contributed to im-
proved prognosis in heart failure, but the improvement in mortality has slowed down since the 
beginning of the 21st century. 
Aim: The aim of this thesis was 1) to validate hospital diagnoses of cardiomyopathy; 2) to de-
scribe characteristics of young patients with HF; 3) to evaluate possible changes in mortality 
over time by studying mortality rates, mortality risks and estimation of life-years lost compared 
with matched controls from the general population; and 4) to explore possible sex related differ-
ences among young patients with HF.   
Methods and Results: Through search of local hospital discharge registers at three hospitals in 
western Sweden 611 medical records from 1989 to 2009 with the diagnoses of cardiomyopathy 
were validated against the latest ESC diagnostic criteria. Of all cases a high proportion, 86%, 
fi lled the criteria current at the time of diagnosis. In Paper II, III and IV several Swedish registers 
were combined. In Paper II all patients with incident hospitalization for HF registered in the Na-
tional Patient Register were included. Over two periods, 1987-2002 compared with 2003–1014, 
a decrease in mortality rates were observed mainly among patients <65 years while in patients 
65 years only minimal improvement in survival was found. As mortality rates decreased more 
in matched controls from the general population the relative mortality risk increased in patients 
<65 years during the observed period. In Paper III and IV, all patients from the Swedish Heart 
Failure Register were included from 2003 to 2014 and patients <55 years were compared with 
those 55 years and matched controls <55 years with regard to patient characteristics, mortality 
rates and mortality risk. Patients <55 years had higher rates of concomitant cardiomyopathies, 
myocarditis, obesity, congenital heart disease and reduced ejection fraction (EF) while older pa-
tients had more ischemic heart disease, hypertension and atrial fi brillation. Mortality rates were 
lower among the patients <55 years but when compared to controls they had fi ve times higher 
mortality risk and patients 18-34 years of age had up to 38 times higher mortality risk. When 
compared with the estimated life expectancy of the general population the youngest patients lost 
up to 26 life-years, this declined with increasing age. Women, compared to men, had higher rates 
of obesity, congenital heart disease, hypertrophic cardiomyopathy, midrange and preserved EF 
while men had more ischemic heart disease, atrial fi brillation and more often reduced EF. In ab-
solute numbers there was no difference in mortality rates, but women with HF had almost twice 
as high mortality risk relative to controls than did men (even though not signifi cant) and lost 
more life-years than men. The most common cause of death was cardiovascular death (CVD) 
followed by cancer, presence of the latter was associated with doubled mortality risk in men 
and a 3-fold increase in risk in women, relative to men and women without concomitant cancer.
Conclusion: The validity of the cardiomyopathy diagnoses was high supporting the hypo- 
thesis that a real increase of cardiomyopathy might have occurred. Survival of patients with HF 
improved among patients <65 years while among those older patients the improvement was mar-
ginal. The mortality risk relative to age-matched controls increased among the younger group, 
as the mortality reduction was more pronounced among controls. The younger the patients the 
higher estimated life-years lost. The most common mode of death was CVD followed by cancer 
in both sexes. Cancer was associated with increased mortality risk in both sexes. 
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MAGGIC  Meta-analysis Global Group in Chronic Heart Failure
MRA   Mineral corticoid receptor antagonists
NT-proBNP  N-terminal prohormone of brain natriuretic peptide
PIN   Personal identity number
RAAS   Renin angiotensin aldosterone system
RCT    Randomized clinical trials
SD   Standard deviation 
SGLT2   Sodium-glucose cotransporter-2 inhibitor 
SwedeHF  The Swedish Heart Failure Register
UK   United Kingdom
US   United States
WHO    World Health Organization
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 INTRODUCTION
Defi nition and diagnostic criteria for heart failure
Heart failure (HF) is a common and serious syndrome(1). Over the years the defi nition 
of HF has been revised several times. In the latest guidelines of the European Society 
of Cardiology (ESC) from 2016, HF was defi ned as “a clinical syndrome charac-
terized by abnormalities of left ventricular function and neuro-hormonal regulation 
which are accompanied by effort intolerance, fl uid retention and reduced longevity”(2).
Guidelines provide practical and evidence-based recommendations to medical profes-
sionals in everyday clinical practice for management of acute and chronic HF. Histori-
cally, several diagnostic criteria for HF have been available including the Framingham 
criteria from 1971(3), Duke criteria from 1977(4), the Boston criteria from 1985(5) and 
the Gothenburg criteria from 1987(6). In 1995 the ESC presented their fi rst diagnostic 
criteria for HF(7) that over years has been updated on a regular basis (in 2001, 2005, 
2008, 2012 and 2016). The latest criteria is based on symptoms and clinical signs, 
measurement of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 
and echocardiography examination(2). The criteria are implemented in the Swedish 
health care programmes with local adjustments. 
The epidemiology of heart failure
HF is a major health problem with high morbidity and mortality, including extensive 
healthcare costs globally(8-11). The prevalence of HF in an adult population in devel-
oped countries has been estimated at about 1-2%(12-14). Data from Stockholm county 
based on data from 2.1 million inhabitants showed a HF prevalence of 2.2%(15). HF 
primarily affects older people and in the population above 70 years of age the preva-
lence increases to more than 10%(16). Even though HF is more common among the 
elderly, it may also occur in the young(3, 8, 16). In previous papers using data from the 
National Patient Register (NPR) in Sweden, both hospitalization(17) and prevalence(13) 
of heart failure increased among young adults. It is resonable to belive that young 
patients are hospitalized for comprehensive evaluation when they are diagnosed with 
HF. Thus the increase in hospitalization rates may mirror true incidence increase. Ad-
ditionally, the authors showed that hospital discharges with cardiomyopathy diagno-
ses, a known cause of HF, increased in all age groups, most pronounced among young 
patients, almost tripling between 1987 and 2006 in the age category 18-44 years of 
age(17). The prevalence of obesity, a known risk factor for HF, is increasing world-
wide(18) and in Sweden(19-21), in all age groups and recently, an association between 
obesity and cardiomyopathy has been demonstrated(22). 
During the last decades, new treatment modalities were developed resulting in prog-
nostic improvement in selected groups of patients with HF. In addition, improved 
treatment of hypertension and ischemic heart disease (IHD), the most common causes 
of HF, may have contributed to decreased incidence of HF in the older subset of the 
population. Previous reports from Sweden showed improvement in survival up to 
2003 especially in men < 65 years with HF of ischemic origin(23). However, changes 
in mortality trends have been observed recently, where, in contrast to the fast sink-
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ing mortality until 2010, a deceleration in the reduction of cardiovascular mortality 
has been witnessed in the US(24), and in the UK only modest improvements in sur-
vival were seen in patients with HF from the beginning of 21st century until 2017(25). 
A similar decelerating trend in the mortality reduction in individuals with HF was 
observed in Sweden after 2003, where only a marginal decrease in mortality was re-
ported from Stockholm county from 2006 to 2010(26). A recently published nationwide 
study showed decreasing both all-cause and CVD related mortality but still combined 
with high mortality rates(27). 
It has been speculated on that the aging population may contribute to potential HF 
“epidemic”(28). So far, an epidemic of HF has not been confi rmed in Sweden. How-
ever, with the increasing trends of  HF in the young and increasing life expectancy, 
an increase in HF might be anticipated in the near future, especially with increasing 
rates of obesity in the young(20), with documented associations with early-onset heart 
failure and cardiomyopathies(21, 22). The implementation of evidence-based treatment 
has led to prognostic improvement, but in patients with HF and preserved ejection 
fraction (EF), that are more frequently older, women and with obesity(29-31), so far, no 
trial showed treatment to improve prognosis(32-38). This may, to some extent, with an 
aging population, have contributed to the decelerating mortality trends that have been 
observed. Even though the overall mortality has improved, the mortality rates still 
remain high in both stabile patients 6-7%(39, 40) and up to 25%(41, 42) in patients hospital-
ized after acute decompensation. Recently published data from Canada presented high 
mortality rates also in young patients with HF(43). 
In summary, several factors have changed over time that may have had an impact 
on the survival of patients with HF in different age categories. It is reasonable to 
expect a difference in the risk factor profi le in the general population as well, as the 
estimated life expectancy of the general population in most countries is increasing(44). 
Consequently, the mortality risk in patients with HF compared with that of the general 
population still needs to be addressed over time and in different age categories for 
both sexes. 
Causes and co-morbidities in patients with heart failure
There is always an underlying cause of HF, where hypertension and IHD can be found 
in 75% of cases. In addition, HF can be caused by a variety of other conditions such 
as congenital heart disease, valve disorders, endocrine disorders, systemic diseases 
and cardiomyopathies(2). Among cardiomyopathies, hypertrophic cardiomyopathy, an 
inherited disease(45), is sometimes associated with HF, while in dilated cardiomyopa-
thy it is almost always the case(46). Dilated cardiomyopathy is a heterogeneous group 
where idiopathic dilated cardiomyopathy predominates. Also heart failure may arise 
in conjunction with rapid heart rhythm disorders, general   muscle disorders, in con-
junction with pregnancy and childbirth in women, and may be due to toxic substances 
such as alcohol, amphetamine and use of cytostatic(46). HF may be accompanied with 
other disorders and sometimes it may be diffi cult to differentiate between causes and 
co-morbidities, such as the very frequent co-morbidities in patients with HF repre-
sented by IHD, diabetes mellitus, hypertension or atrial fi brillation (AF)(47).
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Classifi cation of cardiomyopathies
Cardiomyopathies represent a heterogeneous group of diseases(46). Over years the 
defi nition and classifi cation has changed as the understanding and knowledge about 
the entity increased(46, 48-51). During the 1980s, cardiomyopathies were defi ned as heart 
muscle disorder of unknown cause, but with other forms in the group of specifi c heart 
muscle disorders with known cause or related with disorders in other systems. Physi-
cians were often challenged with diffi culties to distinguish these two categories as car-
diomyopathies to a great extent may affect other organ systems(48). With the growing 
body of evidence in the area of pathogenesis, genetics and etiology there was recently 
a new update of the diagnostic criteria from the European Society of Cardiology, 
where cardiomyopathies were defi ned as “heart muscle disease with cardiac dysfunc-
tion” in the absence of cardiac malfunction due to hypertension, coronary artery oc-
clusion, valve disease or congenital heart disease(50). 
The most recent classifi cation by the ESC was introduced in 2008 with a clinically 
oriented approach, grouping cardiomyopathies with respect to ventricular morphol-
ogy and function. Since then cardiomyopathies are defi ned as: “A myocardial disease 
in which the heart muscle is structurally and functionally abnormal, in the absence of 
coronary artery disease, hypertension, valve disease and congenital heart disease suf-
fi cient to cause the observed myocardial abnormality.” To raise the awareness about 
hereditary forms all cardiomyopathies were divided into familial or idiopathic forms. 
Besides, those induced by viral infection, infl ammatory disease, tachycardia, in rela-
tion to pregnancy or toxic effect of alcohol and/or drug abuse or medications were 
also included. This resulted in a broader and more comprehensive defi nition of the 
cardiomyopathy diagnoses that historically was established with elimination of other 
major causes of cardiac dysfunction(46).  
Classifi cation of heart failure in regard to ejection fraction 
The use of imaging methods, such as echocardiography, enables the evaluation of left 
ventricular EF. According to the current ESC guidelines, patients with HF may have 
left ventricular EF 50%, preserved EF (HFpEF), EF 40-49%, midrange EF (HFmrHF), 
or reduced LVEF <40%, HF with reduced EF (HFrEF)(2). 
Patients with HFpEF were more often older, women and with history of hypertension 
and AF, while history of IHD was less common compared with patients with HFrEF(52, 53). 
Two previous studies, a clinical trial and a meta-analysis(54, 55) that compared patients with 
HF in different age groups, showed that younger patients had higher rates of reduced 
EF (<40%) than the elderly.
Age categories 
In epidemiological studies analysis by age are widely used, mostly to adjust for con-
founding. When forming age categories, one important aspect is comparability with 
other studies. One of the recommendations of the international journal of epidemio-
logy for group forming is to use mid-decade to mid-decade groups(56). 
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The United Nations Department of Economics and Social Affairs, Population Di-
vision has proposed that the population may be divided into following age groups: 
1) Children and adolescence 0 to 20 years; 2) “young adults” 20 to 39 years; 3) “mid-
dle-aged” adults 40-59 years; older persons 60 years of age(57). 
A previous national study from the NPR assessing survival of patients with HF 
relevant for this doctoral thesis used the age of 65 years to defi ne the older (65 years) 
and younger (<65 years) age groups(23). To increase comparability in part II of this 
thesis the same cut off of 65 years was used. Also, two other studies(13, 17) showed an 
increase in hospitalizations and prevalence of HF in the age group 18 to 54 years of 
age. In order to enable comparison with these studies in part III and IV of this thesis, 
younger age groups were defi ned as individuals <55 years.  
Treatment of chronic heart failure
Current recommendations for treatment of HF are based on symptomatology and EF. 
The use of several drugs and devices has been shown to have benefi cial effects on 
morbidity and mortality in patients with reduced EF. However, all studies to date have 
been neutral for patients in the EF group 50%(33-35). For patients with HFmrEF so far 
there are only subgroup analyses of previous major clinical trials demonstrating an 
effect on outcomes(58). Hence, all studies with positive effect on mortality, so far, were 
performed in patients with HFrEF(2).
Treatment with diuretics is recommended in patients with symptoms and signs of 
congestion(2, 59), but the effect on mortality have not been studied in randomized con-
trolled trials. Diuretics appear to reduce the mortality risk and risk of worsening heart 
failure when compared to placebo and when compared to active agents improvement 
in exercise capacity was noticed in patients with chronic HF(60).
The neuro-hormonal blocking treatment was established in the 1980s when the inhibi-
tion of the renin angiotensin aldosteron system (RAAS) with the angiotensin convert-
ing enzyme (ACE) inhibitor, reduced overall mortality in HF(61, 62). In the following 
years, the ACE inhibitor enalapril was shown to be benefi cial in reducing hospitaliza-
tions for HF in asymptomatic patients(63). 
In addition, the use of beta-blockers is recommended, based on the mortality benefi t, 
for bisoprolol(64), carvedilol(65) and sustained-release metoprolol(66). Angiotensin re-
ceptor blocker (ARB) therapy was not proven to be superior to ACE inhibitors(67) and 
therefore the treatment with ARB is indicated in case of intolerance of ACE inhibitors 
and in patients on treatment with an ACE inhibitor but unable to tolerate a mineralo-
corticoid receptor antagonist (MRA). The MRA spironolactone was proven to reduce 
mortality in patients with HF with severe symptoms(68) and in 2011 eplerenone was 
proven to reduce mortality even in patients with mild symptoms(69). Ivabradine, which 
is a sinus node inhibitor, reduced the composite endpoint of CVD or hospitalization 
for worsening HF in patients with HFrEF and sinus rhythm(70). In 2014 the combina-
tion of ARB (valsartan) and a neprilysin (NEP) inhibitor (sacubitril) has been shown 
to be superior to enalapril in reducing the risk of death and hospitalization(71). 
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Studies with hydralazine and isosorbide dinitrate causing vasodilatation, compared 
with placebo have also shown reduction in mortality(72), but the combination was less 
effective when compared with an ACE inhibitor. On the other hand, treatment with 
digoxin showed no mortality reduction when compared to placebo but a reduction in 
hospitalization rates was seen(73).
Studies in the area of cardiac devices has shown benefi cial effects of cardiac resyn-
chronization therapy (CRT)(74) and implantable cardioverter-defi brillators(75) in terms 
of mortality in selected patient groups where CRT treatment also showed benefi cial 
effects concerning hospitalization rates, even in patients with mild symptoms(76). After 
the publication of the most recent guidelines from the European Society of Cardiology 
(ESC) new treatments, such as sodium/glucose cotransporter 2 (SGLT2) inhibitors 
that are used to lower plasma glucose in patients with diabetes, have shown favorable 
effects in patients with HF, also among patients without diabetes(77). 
Differences between men and women with heart failure
Accumulating knowledge about sex differences increases the awareness and a need 
for different approaches in women and men, when treating cardiovascular disease(78, 79). 
Several studies have highlighted the differences between men and women with HF, from 
clinical presentation to treatment, but the results refer mainly to the elderly(80-83). 
Both observational studies and randomized clinical trials (RCT) show that women 
with HF are older than men(80). They also describe that women more often have con-
comitant hypertension, renal failure, obesity and depression whereas men with HF 
more often have IHD, chronic obstructive pulmonary disease (COPD) and HF with 
reduced EF(84-86). Women have more severe symptoms, but appear to have better 
overall survival(81-83). Also, women are less likely to receive guideline recommended 
therapy then men(87). Accordingly, men and women with HF differ in clinical aspects 
as age, co-morbidities and treatment(80, 88, 89). Mortality in patients with HF is high, par-
ticularly in older patients, but mortality in the young is also substantial(17, 43). Between 
1987 and 2006 young men with HF had a higher mortality than women(17). Mortality 
risk in elderly patients with HF (mean age 73 years) from the Framingham Heart study 
was fourfold higher than in age and gender matched control subjects without conges-
tive HF(90). In a middle-aged community-based population sample with an observation 
period of two decades women had lower risk of developing HF, they had lower all-
cause mortality and death related to HF, but in established HF there was no difference 
in mortality risk between the sexes(91). 
International classifi cation of disease 
International Statistical Classifi cation of Diseases (ICD) and Related Health Problems, 
has existed about one hundred years enabling classifi cation and statistical evaluation 
of health problems in patients within the health care system. Thus, all diagnoses in 
medical records are coded using ICD codes. The World Health Organization (WHO) 
has been responsible for the maintenance of ICD since 1948. Over time, the ICD sys-
tem has been revised and updated in accordance with advances in science, and since 
May 1990 ICD-10 version has been acknowledged (used in Sweden since 1997).
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Swedish registers
There is a long history of registry holding in Sweden. The fi rst records of demographic 
data were maintained by church offi cials already in the 17th century. Since 1947 all 
persons with residence in Sweden have been assigned a personal identity number 
(PIN). The use of the current 12-digit PIN, in use since 1967, enables the linkage of 
different registers(92). 
All residents in Sweden are registered in the Swedish Population Register, begin-
ning in the 1960s. The register contains demographic data, eg. date of birth, sex and 
county(93).
The Swedish Hospital Discharge Register, also called Swedish National Inpatient 
Register was established in the1960s. In 1987 the registrations of hospitalized patients 
became mandatory on a national level. Currently, the coverage of the register is more 
than 99%. The register records principal and contributory diagnoses, procedure codes, 
admission and discharge dates of all hospitalizations. The register has a high valid-
ity in general, in particular for HF with an 85–95% accuracy compared with patient 
records(94, 95). 
The Swedish Cause of Death Register started in 1961 and contains data on time and 
cause (underlying and contributory) of death for all deceased persons in Sweden. Data 
that is also available on the location of death, if autopsy was performed or if the cause 
of death was established through an examination before death, and if the person had 
had an operation within the last four weeks. Prior to 2012 only Swedish residents were 
registered(96). 
The Swedish Heart Failure Register (SwedeHF) is a nationwide, voluntary quality 
register for patients diagnosed with HF. It was introduced throughout Sweden in 2003 
including hospitalized patients, outpatient’s and in primary care units. Inclusion crite-
rion is physician-judged HF diagnosis. The multisite ethics committee approved the 
establishment and operation of the register. Individual patient consent is not manda-
tory but patients are informed and may opt out(97). 
Observational studies
In observational studies the investigator observes what happens, without interfering. 
They are often used in epidemiological studies to assess the relationship between the 
factors of interest and disease in the population and may be addressed retrospectively 
or prospectively. Main types of observational studies are cohort studies and case-con-
trol studies. In cohort studies a group of individuals is followed over a defi ned period 
of time and the aim is to study whether a factor of interest will affect the incidence of 
a disease outcome. A comparison of groups of patients with a specifi c disease (named 
cases) and individuals without that disease (named controls) is performed in case-con-
trol studies and the aim is to investigate if exposure to any factor occurs more or less 
often in patients than in the control group. Selected controls and controls should be 
similar in selected characteristics, such as age and sex. This process is called match-
ing. To add power to the study more controls should be included than cases and for 
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statistical reasons it is usually enough with two controls per patient. In longitudinal 
studies individuals are followed over a period of time. In cross-sectional studies all 
information is obtained at a single point in time, providing information on prevalence 
estimates or current health status of a group of patients. Cross-sectional studies may 
also be repeated enabling information on changes over time. 
Term used to defi ne the occurrence of a condition of interest in the population is 
prevalence. Incidence is a measurement of the probability of a condition`s occurrence 
in a population within a defi ned time frame. Mortality is defi ned as a number of deaths 
in a population in a specifi ed time period. Prevalence of a chronic disease depends on 
the rate of newly diagnosed cases (the incidence), potential recovery (for some condi-
tions), and all-cause mortality. These commonly used terms (prevalence, incidence 
and mortality) may be presented as proportions, percentages or number of cases, per 
1,000, 10,000 or 100,000 individuals. Incidence and mortality are often expressed as 
cases or deaths occurring within a specifi c number of observation years, eg. per 1000, 
10,000, or 100,000 person years.
Survival analysis 
Survival analysis is a set of methods to study the time necessary for an individual to 
reach an endpoint of interest (death, hospitalization). Important features are the length 
of time for the individual to reach the endpoint and censoring due to incomplete in-
formation on the outcome. Data might be left-censored in patients in whom follow 
up begins after baseline date. Right-censored data comes from patients who has not 
reached the endpoint at the time point they were lost to follow up, were withdrawn 
from the study, or where , for some reason, follow up had been stopped before the end-
point was reached. Usually, individuals are included continuously in a study, which 
means that different individuals have different follow-up times at the end of the study, 
further complicating survival data. 
One way of displaying the survival data is the use of survival curves, usually calcu-
lated by the Kaplan-Meier method and presents the cumulative probability of an indi-
vidual remaining free from endpoint at any point during follow up. An advantage of 
this method is that it takes into account for example right-censoring, but is not suited 
to estimate survival adjusted for covariates. 
The log-rank test is a non-parametric test used to compare two or more survival 
curves. Kaplan-Meier curves and log-rank test present univariate analysis of categori-
cal variables, describing the effect of one factor on survival and ignoring the impact 
of any other factors. 
Often used in survival analysis is the alternative proportional hazards regression model 
(Cox regression) that enables the study of the concurrent effect of a number of explana-
tory variables on survival. Originally the model was proposed for clinical trials but 
soon it was embraced in epidemiological observational studies and nowadays it is 
usually used in cohort and case-controls studies frequently involving long follow up 
time and numerous known and unknown factors, and works for both quantitative and 
categorical explanatory variables. This type of model simultaneously addresses the ef-
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fect of several factors on survival time. The effect is reported as a ratio for an outcome 
of interest. In survival analysis hazard presents the immediate risk of reaching the 
endpoint. Hazard ratio (HR) is the ratio of two hazards also known as relative hazard 
and is interpreted in a similar way as relative risk. The ratio of two risks is known 
as relative risk, for example the risk of disease in a cluster of individuals exposed to 
some factor divided by the risk in unexposed individuals. The basic condition in the 
proportional hazard regression model is that the relative hazard is constant over time. 
One or more explanatory variables may be related to each other and to the outcome. 
Then it is diffi cult to assess the independent effect of one variable on the outcome. 
This is called confounding. There are different methods to adjust for confounding 
such as multi-variable Cox regression model for estimation of risk. 
Conditional probability is the probability of an event, assumed that another event has 
happened. Life expectancy is defi ned with statistical methods as estimated average 
time an individual or group of people are expected to live, based on the year of birth, 
current age, also including other demographic factors such as gender, and is often 
presented in life expectancy tables. Life expectancy is expressed as average and an 
individual may die many years after or before the “expected” survival. Conditional 
survival is the life expectancy from a point in time for an individual who already sur-
vived a certain period after disease start. In other words, it is the survival probability 
calculated after a certain length of survival and takes only into account individuals 
that survived to that point. Consequently it might be looked on as an update of life 
expectancy.
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THE RATIONALE OF THE THESIS
Paper I 
Today we do not know whether the observed increase in cardiomyopathy diagnoses(17) 
represents a real increase of the disease or whether the diagnosis setting is based on 
other reasons today compared to the late 1980s. Consequently, validating the diagno-
sis is an important step.
Paper II
With an aging population, advances in treatment and changes in risk factor profi le(98), 
even potential changes in mortality trends in patients with HF over time are of inter-
est. No study so far investigated the survival of patients with HF and explored pos-
sible changes of mortality risks compared to controls from the general population over 
time on the national level with emphasis on different age categories and in both sexes. 
Paper III
Young patients were described in comparison to elderly patients in selected patient 
populations(54, 55), or with data sets not reporting data on echocardiography results or 
prevalence of co-morbidity such as cardiomyopathy(43), or including subset of young 
patients with preserved EF only(99). Accordingly, a detailed and comprehensive de-
scription of the growing subset of young patients with HF in a less selected population 
is needed.
Paper IV
Sex differences in elderly patients with HF are well described(80-83), while in young 
patients these are, to our knowledge, still to be addressed.
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AIMS
Paper I
The aim of this study was to examine the accuracy of cardiomyopathy diagnoses and 
evaluate if there were changes in validity over time from 1987 to 2009, taking into 
consideration possible changes in the use of diagnostic methods and potential changes 
in prevalence of coǦmorbidities. 
Paper II
This study aims to investigate short-term and long-term mortality in patients fi rst time 
hospitalized for HF and compare survival in patients with HF with controls from the 
general population and to assess potential changes of the mortality risk over time in 
different age categories and in both sexes. 
Paper III
The aim of the study is to compare clinical characteristics, treatment and outcomes 
of patients with HF <55 years and those 55 registered in the SwedeHF. In addition, 
to study survival of patients <55 years in comparison with matched controls from the 
general population and investigate the risk for all-cause mortality and life-years lost 
after being diagnosed with HF in young age. 
Paper IV
This study aims to compare clinical characteristics, management and causes of death 
between sexes in patients with HF <55 years. Also, to compare mortality risks, and 
estimate potential loss of life-years in men and women with HF <55 years compared 
with those of matched controls. We also wanted to investigate the impact of baseline 
co-morbidities on mortality in young men and women with HF, respectively.
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METHODS
Paper I
Patients from 1989-90, 1994-96, 1997-99, 2004 and 2009 with a cardiomyopathy 
diagnosis, irrespective of the diagnostic position, in both outpatient and inpatient set-
tings were identifi ed from the local hospital discharge registers with the use of the 
International Classifi cation of Diseases (ICD) codes. From 1987 to 1996, ICDǦ9 was 
in use, and thereafter ICDǦ10. ICD codes for all hospital discharges are entered into 
the Swedish National Inpatient Register, mandatory on national level since 1987. Pa-
tient records were divided into three groups: dilated, hypertrophic, and other cardio-
myopathies. Hypertrophic and hypertrophic obstructive cardiomyopathy formed one 
group. Due to few cases, cardiomyopathies such as peripartum, restrictive, arrhyth-
mogenic right ventricular, left ventricular nonǦcompaction and takotsubo cardiomy-
opathies were analyzed as one group labeled “other cardiomyopathies”. Diagnoses 
were then validated according criteria defi ned by the European Society of Cardiol-
ogy from 2008(46). The accuracy of the diagnoses was categorized as defi nite, uncer-
tain or miscoded. In undecided cases, two very experienced cardiologists read the 
records separately and then a joint decision was made. Also, 20 medical records were 
randomly selected, and two experienced cardiologists validated the cardiomyopathy 
diagnoses separately. Finally, 20 medical records with diagnostic code for HF (I50), 
but without a cardiomyopathy diagnoses, were studied for potential occurrence of 
cardiomyopathy as a co-morbidity. Accuracy rates of diagnosis including frequency 
of coǦmorbidities were examined using the Pearson Ȥ2 test for categorical variables. 
Student’s tǦtest was used for continuous variables. All p values are two sided, values 
<0.05 were considered statistically signifi cant. All statistical analyses were performed 
using SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA).
Paper II
For the purposes of this study all patients 18 years with a fi rst recorded hospitaliza-
tion for HF and registered in NPR between January 1st, 1987 to December 31st, 2014 
were included. With the use of personal identifi cation number two controls per patient 
were selected from the Total Population Register. Controls were defi ned as individu-
als without HF and they were matched for age, sex and county. Information on time 
and cause of death were obtained from the Cause of Death Register. 
HF and all co-morbidities were defi ned according to the ICD-9 and ICD-10 codes. 
Codes used to identify comorbidities and causes of death were ICD-9: 410–414, 250, 
401–405, 431, 433, 434, 436, 394-397, 424, 427D, 425, 415B, 490–496, 140–208 
and ICD-10: I20–I25, E10–E14, I10–I15, I61–I64, I05-I08, I34-I37, I48, I42, I43, 
I26, J44, J45, C00–C97. The Kaplan-Meier method was used to assess probability of 
survival with the cohort stratifi ed into two groups: 18–64 years and >65 years, and 
the study period was split from 1987–2002 and from 2003–2014. Cox proportional 
hazard regression was used to assess differences in 1-year all-cause mortality between 
cases and controls and to estimate the relative risk of mortality between cases and 
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controls. All statistical analyses were performed with the statistical software SAS, 
version 9.4 (SAS Institute, Cary, NC) and all graphs were created using R version 
3.1.3 (http://R-project.org).
Paper III and IV
All patients >18 years registered in the SwedeHF from 1st January 2003 to 31st De-
cember 2014 were included. All patients had a minimum follow of 2 years. The data 
set was merged with NPR and Cause of Death Registers with the use of the PIN. The 
population was divided into patients <55 years, and 55 years. Patients with HF <55 
years were further subdivided into three age categories: 18-34, 35-44 and 45-54 years. 
For each patient with HF <55 years, we identifi ed 2 controls from the Total Population 
Register matched for age, sex and county. Controls were defi ned as individuals with-
out a prior HF diagnosis. Co-morbidities were identifi ed from the NPR with the use of 
ICD codes; ICD-9 codes from 1987 to 1996, and ICD-10 codes from 1997. ICD codes 
were also used to identify the underlying and fi rst contributory cause of death from the 
Cause of Death Register. ICD-9 and ICD-10 codes used for the purposes of Paper III 
and IV are presented in Table 1. The latest update of the Cause of Death Register in 
this study was 31st December 2015. All analyses were performed in men and women 
<55 years with HF separately in Paper IV. 
Category  ICD-9 ICD-10 
Heart failure 428 A, 428B, 428X I50 
Other cardiovascular 
diagnoses  
401-405, 410-414, 416A,427D, 425, 425F,  
425E, 425B, 674W, 391, 394-398, 421, 422, 424, 745-747 
I10-I15, I20-I25, I27.0, I40- I41, I48, I42.0, I42.1, I42.2, O90.3 
I05-I09, I33-I39, Q20 - Q28, Q87, Q89  
Diabetes mellitus 250 E10-E14 
Obesity 278A, 278B E65-E66 
Depression  296, 296B, 296D, 296W, 296X,298A, 331 F32-F33 
Kidney disease 583, 584, 585 N17-N19 
Cancer 140-208 C00-C97 
Table 1. International Classifi cation of Diseases ICD-9 codes and ICD-10 codes used to identify 
co-morbidity in the National Patient Register
For comparison between continues variables the Student’s t test and for categorical 
variables the Pearson chi-square test were used. The impact of age on different co-
morbidities was tested with logistic regression with adjustment for sex. Compared 
with controls, for patients <55 years the association between age at inclusion and risk 
for all-cause mortality was tested with Cox proportional , both univariate and multi-
variate models as purposed by Rawshani et al.(100). 
The conditional survival was estimated for patients and presented as median. As ref-
erence to the life expectancy of controls, life expectancy tables from Statistics Swe-
den,12 were used. These are available at the website: http://www.statistikdatabasen.
scb.se/pxweb/sv/ssd/START_BE_BE0701/LivslUtbLan/. The conditional survival 
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for patients and conditional life expectancy for controls were estimated at 30, 35, 40 
and 45 years of age. The difference between life expectancy and conditional survival 
for patients with HF was defi ned as life-years lost and is presented as median. All p 
values are two-sided and p<0.05 was considered statistically signifi cant. All statistical 
analyses were performed using SPSS, Windows version 18.0 (SPSS Inc., Chicago, IL, 
USA), SAS 9.3 or in R 3.5.3. This study was approved by the Ethics Committee of the 
University of Gothenburg, Sweden. 
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RESULTS
Paper I
In total 611 medical records with cardiomyopathy diagnoses were validated. Mean 
age of the population was 58.9 (SD 15.5) years, 68.2% were male. The records were 
divided into those with dilated, hypertrophic and other cardiomyopathies with 85.5%, 
87.5%, and 100% of accuracy, respectively. The accuracy of diagnosis DCM and 
HCM/HOCM by year are presented in Figure 1 and 2. The use of echocardiography 
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Figure 1. Accuracy of the dilated cardiomyopathy (DCM) diagnose by year.
Figure 2. Accuracy of hypertrophic and/or hypertrophic obstructive 
cardiomyopathy (HCM/HOCM) diagnoses by year.
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Figure 3. Use of echocardiography by year in the whole population studied.
was high, performed in 99.7% of cases, of which 94.6% were complete reports (Fig-
ure 3). The use of echocardiography was consistently high during the study period and 
without signifi cant difference between periods studied or between hospitals. The pres-
ence of co-morbidities, hypertension, coronary artery disease, diabetes mellitus, AF 
and alcohol and/or drug abuse, was also analyzed. During the study period there was 
no systematic variation of any co-morbidity, in the whole material, nor in the subset 
with the accurate cardiomyopathy diagnoses. 
Paper II
The total population comprised 702,485 patients with HF (49.8% men and 50.2% 
women) and 1,306,183 controls. In patients aged 18 to 65 years, both short-term (29 
days to 6 months) and long-term (<11 years and >11 years) mortality rates decreased 
during the study period, but in patients 65 years the decrease in mortality rates was 
marginal (Figure 4 and 5). Compared to controls, HF patients aged <65 years had 
a relative mortality risk at 29 days to 6 months of 3.66 (95% CI 3.46-3.87) during 
1987-2002, but the relative risk was considerably higher 2003-2014 with the HR 11.3, 
95% CI 9.99-12.7. Also, long-term mortality (>11 years) increased from 3.16, 95% 
CI 3.07-3.24 in 1987-2002 to 4.11, 95% CI 3.49-4.85 in 2003-2014 (Figure 6 and 7). 
Similar, but less pronounced alterations between the two periods were seen in patients 
65 years. The increase in mortality risk over time in both age groups mainly may be 
explained by the more marked improvement of survival in controls than in patients. 
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Figure 5. Mortality rates per 1000-person-years in the period 2003-2014 in patients with heart 
failure and controls by age group.
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Figure 4. Mortality rates per 1000-person-years in the period 1987-2002 in patients with heart 
failure and controls by age group.
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Figure 6. Relative risk of death in patients with heart failure compared to controls from the 
general population by age group between 1987 and 2002.
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Figure 7. Relative risk of death between 2003 and 2014 in patients with heart failure compared 
to controls from the general population by age group.
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Table 2. Frequency of co-morbidities in different age groups and by sex in patients with heart failure. 
Data originates from the Swedish Heart Failure and National Patient Registers
  All patients Patients <55 years 
  Patients 
<55 years 
n=3752
Patients 
 55 years 
n=57210
p-value  
Patients  
<55 vs  
 55 years
Men 
n= 2781  
Women 
n=971  
p-value  
men vs. 
women
Obesity  367 (9.8) 2706 (4.7) <0.001 245 (8.8) 122 (12.6) 0.001
Ischemic heart disease 972 (25.9) 31982 (55.9)  <0.001 768 (27.6) 204 (21.0) <0.001 
Atrial fibrillation  933 (24.9) 31364 (54.8) <0.001 763 (27.4) 170 (17.5) <0.001 
Hypertension  1186 (31.6) 33197 (58) <0.001 906 (32.6) 280 (28.8) 0.002 
Diabetes mellitus  627 (16.7) 14975 (25.6) <0.001 476 (17.1) 147 (15.1) 0.154 
Valvular disease  467 (12.4) 11556 (20.2) <0.001 333 (12.0) 134 (13.8) 0.138 
Dilated cardiomyopathy 1020 (27.2) 3165 (5.5) <0.001 967 (34.8) 338 (34.8) 0.983 
Hypertrophic cardiomyopathy* 75 (2.0) 532 (0.9) <0.001 45 (1.6) 30 (3.1) 0.005 
Myocarditis  78 (2.1) 257 (0.4) <0.001 55 (2.0) 23 (2.4) 0.462 
Congenital heart disease 140 (3.7) 456 (0.8) <0.001 75 (2.7) 65 (6.7) <0.001 
Cancer   320 (8.5) 14175 (24.8) <0.001 165 (5.9) 155 (16.0) <0.001 
Values are expressed as numbers (percentages) unless otherwise stated. *Hypertrophic cardiomyopathy - together with patients 
with hypertrophic obstructive cardiomyopathy   
Paper III and IV
In total, 60,962 patients were included. Out of those 3,752 (6.2%) were <55 years 
and they were compared to 7,425 controls. Among patients <55 years, 2781 (74.1%) 
were men and 971 (25.9%) were women, mean age 46.4 (7.3) and 44.9 (8.4) years, 
respectively. Patients <55 had more often obesity, dilated cardiomyopathy and con-
genital heart disease compared to patients 55 (Table 2). EF <40% was also more 
common in patients <55 years, 67.9% vs. 45.1% (p<0.001) compared to patients 55. 
Patients 18-34 years of age had more often HFpEF and HFmrEF than HFrEF. Hyper-
tension, IHD and AF were more common in male patients <55 years while congenital 
heart disease and obesity were more often found in female patients (Table 2). Patients 
had signifi cantly higher frequency of co-morbidities when compared to controls <55 
years. There was no signifi cant difference in treatment among young men and women 
with EF<40% (Figure 8).
One-year all-cause mortality was highest in patients >55 years of age, 21.2% vs. 4.2% 
in those <55 years, and only 0.3% in controls (all p<0.001). One-year all cause mortal-
ity in men and women <55 years was 16.5% and 14.8%, respectively. Total observa-
tion time was 12 years, median 4.87 years. In a multi-variable Cox regression model 
adjusted for age, sex, duration of HF, IHD, diabetes mellitus, dilated cardiomyopa-
thy (DCM), hypertrophic cardiomyopathy/hypertrophic obstructive cardiomyopathy 
(HCM/HOCM), and cancer patients <55 years compared with controls had fi ve times 
higher mortality risk; HR 5,48 (4.45-6.74) with the highest relative risk among the 
youngest patients 18-34 years; HR 38.3 (8.69-168) (both p<0.001). Cancer at baseline 
was associated with increased mortality risk almost three times in patients, HR 2.79 
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Figure 8. Treatment in men and women <55 years with ejection fraction <40%. Data originates 
from the Swedish Heart Failure Register.
Men Women 
HR (CI 95%) **  p-value HR (CI 95%) **  p-value 
Age 1.02 (1.01-1.04) 0.0008 1.03 (1.01-1.05) 0.0165 
Ischemic heart disease 1.28 (1.05-1.57) 0.0166 1.17 (0.80-1.71) 0.4191 
Diabetes mellitus 1.74 (1.42-2.14) <0.0001 1.67 (1.13-2.46) 0.0093 
Dilated cardiomyopathy 1.10 (0.89-1.35) 0.3753 0.70 (0.46-1.06) 0.0947 
Hypertrophic cardiomyopathy* 0.85 (0.37-1.94) 0.7004 2.46 (0.95-6.36) 0.0638 
Congenital heart disease† 1.29 (1.01-1.65) 0.0404 1.73 (1.17-2.55) 0.0060 
Pulmonary arterial hypertension 4.20 (1.85-3.13) <0.0001 7.91 (2.87-21.86) 0.0001 
Cancer 2.40 (1.85-3.13) <0.0001 3.18 (2.27-4.46) <0.0001 
Kidney disease 1.68 (1.23-2.29) 0.0012 3.92 (2.31-6.64) <0.0001 
Duration of heart failure 1.08 (1.05-1.10) <0.0001 1.03 (0.98-1.09) 0.2288 
Abbreviations: HR, hazard ratio; CI, confidence interval. *Hypertrophic cardiomyopathy – together with hypertrophic 
obstructive cardiomyopathy.†Congenital heart disease – together with valve disease. **Adjusted for age, IHD, diabetes 
mellitus, dilated cardiomyopathy, hypertrophic cardiomyopathy/hypertrophic obstructive cardiomyopathy, pulmonary 
arterial hypertension, congenital heart disease, valve disease, cancer, kidney disease and duration of HF. 
Table 3. Impact of coexisting conditions at baseline on total mortality in patients with heart failure 
<55 years by sex. Data originates from the Swedish Herat Failure, National Patient and Cause of 
Death Registers.
(2.29-3.41) (Table 3). Compared to controls, patients lost 26.1, 23.5, 20.6 and 19.1 
life- years when estimated at 30, 35, 40 and 45 years of age. Mortality risk and life-
years lost declined with increasing age. In men and women with HF <55 the relative 
mortality risk was 4.29 (3.39-5.44) and 7.06 (4.33-11.5), respectively (p-value for in-
teraction 0.1185). Women lost up to 2.9, 1.1 and 3.8 years more than men if HF at 35, 
40 and 45 years of age. CVD was the most common cause of death, 58.9% vs 50.7% 
in male vs female patients <55 years, respectively. Cancer was the second most com-
mon cause of death, 9.1% vs. 22.2% in men and women, respectively (all p<0.001).  
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DISCUSSION
Heart failure is a serious syndrome with overall fi ve-year survival of approximately 
50%(16). HF may occur in all age groups but the highest prevalence is among elderly(101). 
There is always a cause to HF(2, 26). Cardiomyopathies present an important etiological 
group, especially in young, where approximately 20% of hospitalized patients with 
HF are diagnosed with concomitant cardiomyopathy(17). Recent studies showed an in-
crease in hospitalization(17) and prevalence(13) of diagnosed HF among young patients 
since 1987, including increasing rates of incident diagnosis for cardiomyopathies(17) 
which is worrying as it may include a very detrimental effect on young individuals. 
Thus, it is important to study etiology, survival trends and mortality risks more in 
detail in this aged group which was performed in the following parts of this thesis: 
Validity of cardiomyopathy diagnoses 
Since 1987 diagnoses of cardiomyopathies had more than doubled among young pa-
tients 18-44 years of age(17). This is of considerable concern as it may imply that a real 
increase of cardiomyopathy disease may have occurred among young patients. 
To our knowledge, this is the fi rst time the validity of cardiomyopathy diagnoses has 
been studied. The accuracy of the diagnoses during a 20 year period (from 1989 to 
2009) was high, >85% (Figure 1 and 2), without differences between the three hospi-
tals or time periods analysed and where the use of echocardiography (Figure 3) over 
time was consistently high. The validations of the diagnoses were performed accord-
ing to the most recent and most comprehensive classifi cation criteria presented in an 
ESC position statement in 2008(46). According to these criteria presence of comorbidi-
ties eg. hypertension or coronary artery disease did not exclude cardiomyopathy if the 
extensions of the associated condition was insuffi cient to cause global impairment of 
cardiac function. Thus, we did not exclude cases from the early years, where in that 
period, cardiomyopathy diagnoses were mostly based on exclusion and presence of 
comorbidities could disqualify from the cardiomyopathy diagnosis(48). Also, use of 
a wider defi nition over time might have involved increasing trends of comorbidities 
over time, which we did not fi nd in this study population.  
Referring to the design of this study, a diagnosis was only considered accurate if ESC 
criteria were met and a complete echocardiography report containing all relevant data 
for decision making was presented in the medical record. Echocardiography was per-
formed in 99.6% of cases, of which 94.5% were complete reports. We also took into 
consideration other data as cardiac markers, electrocardiograms, coronary angiogra-
phy and cardiac magnetic resonance images, if performed.
Because echocardiography had the highest hierarchical order the diagnosis was de-
fi ned as uncertain or wrong if relevant data was not found or if data contradicted the 
diagnosis. In those instances where a dilated cardiomyopathy diagnosis was found to 
be miscoded, this was mostly due to presence of IHD of such magnitude that global 
myocardial dysfunction might be a consequence and in the case of a diagnosis of hy-
pertrophic cardiomyopathy, the presence of long term and/or inadequately treated hy-
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pertension could make in impossible to distinguish between hypertrophic cardiomy-
opathy or hypertrophy caused by hypertension. There were only 20 cases of specifi c 
forms of cardiomyopathies; Takotsubo, peripartum, restrictive, arrhythmogenic right 
ventricular, left ventricular nonǦcompaction cardiomyopathies, that were analyzed to-
gether as one category and defi ned as other cardiomyopathies. Due to very specifi c 
classifi cation criteria(102-106) the validity of this category was 100%, as expected. Di-
agnostic criteria for cardiomyopathies changed over time which might have affected 
diagnostics(7, 48). Therefore, the validation was performed according to the latest and 
most wide diagnostic criteria(46). Consequently, cardiomyopathy diagnosis from ear-
lier periods could have been defi ned as accurate even in presence of comorbidities. 
Even though diagnoses with cardiomyopathy increased over time the occurrence of 
comorbidities did not follow the same increase as expected with widened diagnostic 
criteria or increased recognition. Accordingly, this supports that a real increase of 
cardiomyopathy diseases might have taken place.  Regardless, in the early period we 
detected only few cases. That remaines unclear. Overall, this may mean a real increase 
of cardiomyopathy diagnosis but it is important to take into account that we may have 
missed early cases of cardiomyopathy because the diagnostic criteria were narrower 
then and we therefore might not be able to capture some patients who would have 
been diagnosed with cardiomyopathy at a later stage. Also, 20 medical records with 
the diagnosis of heart failure and without co-morbidities were searched thoroughly 
and in three cases cardiomyopathies were confi rmed in subsequent years after total 
medical workout. This was not likely to affect the validation process but caution is 
needed when hospital discharge registers are used(107, 108), as underestimation of the 
cardiomyopathy diagnoses might be the case.
Survival of patients with heart failure in Sweden
This nationwide study that included more than 700,000 patients with HF and 1,3 
million controls showed that mortality in patients with HF remains high, although an 
overall decrease in mortality rates since 1987 to 2014 has been observed. The survival 
in patients <65 years improved during both periods studied (1987 to 2002 and 2003 
to 2014), but in patients 65 years the survival improved only slightly (Figure 4 and 
5). Overall, only marginal improvements in mortality have been seen in Sweden since 
2003, consistent with the data from UK(25). The improvement in survival, to a great 
extent, refl ected the initial period.  
Short- and long-term mortality was markedly higher in patients than in matched con-
trols from the general population. Additionally, survival improved more among con-
trols than in patients. Consequently, over the two periods, the relative mortality risk 
in patients increased, mainly due to improved survival in the control group. Long 
term mortality risk did not increase to the same extent as the short-term mortality 
risk, mostly due to consistently high HR between 2003 and 2014 (Figure 6 and 7). 
Mortality in patients 65 years remained high and one possible explanation might be 
that the majority of the patients were elderly. As previously described, the proportion 
of patients with HFpEF increased with increasing age, as well as the proportion of 
patients with multiple comorbidities(29, 30, 109). Another explanation to the persistent 
high mortality among patients 65 years might also depend on current lack of treat-
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ment modalities leading to mortality reduction in this patient group, as no study so 
far showed mortality benefi t in patients with HFpEF(32-35, 37), at the same time as there 
is a whole palette of recognized and lifesaving treatment available for patients with 
HFrEF(2). Worryingly, as shown in other studies, many patients are still not offered 
treatment even though they fulfi ll criteria for specifi c treatments(110-114), which also 
may have contributed to the observed mortality trends. Two retrospective studies that 
compared younger with older patients showed that the young more often had HFrEF(54, 
55) and thereby fulfi lled requirements for being treated according to guidelines, with 
potential benefi t with respect to prognosis. However, as presented in a CHARM sub-
group analysis, young patients also had low treatment adherence, which could also 
contribute to explain persistent high mortality rates(54). 
Description and survival of young patients with heart failure with emphasis 
on sex differences in the young
As mentioned above, a recent analysis showed an increase in hospitalization(17) and 
prevalence(13) among patients with HF <55 years. Thus, in part III and IV we focused 
in particular on patients <55 years with HF. Young patients were compared with el-
derly and with controls from the general population with detailed description of young 
patients in SwedeHF with emphasis on gender differences and outcomes compared 
to controls. 
Patients <55 years vs. 55 years
Major differences were present in baseline characteristics, where younger patients 
more often had cardiomyopathies, congenital heart disease and myocarditis and those 
55 years had hypertension, IHD and AF (Table 2), in line with previous studies(54, 
55). Current survival of patients with congenital heart disease into adulthood is 75% 
to 85%(115, 116). They are at increased risk to develop ventricular dysfunction(117, 118) 
and HF. The prevalence of cardiomyopathies in our study was in accordance with 
data previously published in a nationwide study from the NPR(17), but was much low-
er compared to the CHARM subgroup(54) and the MAGGIC meta-analyses(55), most 
probably owing to different study designs. Besides, the CHARM study was included 
in the MAGGIC meta-analysis. Further, the prevalence of obesity was more common 
among the young, in line with other studies(54, 119). Obesity is associated with increased 
risk for early HF(21). Causal relationship between adiposity and HF has also been pro-
posed(120). Recently, an association with obesity in young age and early development 
of cardiomyopathy and known cause of HF, has been suggested(22). 
Young patients were more often threated with guideline recommended therapy(2) than 
elderly patients, probably as they had more often reduced EF, and when indicated (EF 
<40%) young men and women with HF from this cohort were equally treated (Figure 
8), which differs from other studies showing that women were less often offered this 
treatment. However, elderly patients more frequently had HFpEF and thereby lacked 
indication for this treatment. They also, as stated in previous studies, were more often 
less treated probably owing to contraindications and intolerance of medications as a 
reason why physicians may abstain from providing treatment(110-112, 121).  
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Male vs. female patients <55 years
The majority of young patients with HF were men. The prevalence of IHD, hyper-
tension and AF was higher in men, as these conditions are more prevalent in men in 
the general population(122, 123). Also, the later onset of IHD in women compared to 
men(124), might explain the higher occurrence of IHD in men <55 years in this cohort. 
Accordingly, this might also have been refl ected in echocardiography reports, show-
ing a higher prevalence of reduced left ventricular EF in the young, particularly in 
men. Women <55 years more often had congenital heart disease and hypertrophic 
cardiomyopathy which might explain higher occurrence of HFmrEF and HFpEF in 
this group. Besides, young women with HF also had higher rates of cancer and obe-
sity. Detailed analysis of subgroups of congenital heart disease and cancer were not 
performed due to small number of patients and this should be kept in mind when inter-
preting these results. Men and women with HF <55 years and EF <40% were equally 
treated with evidence-based lifesaving treatment(2) which to some extent contradicts 
previous studies showing that women are likely to be less treated(87) (Figure 8). 
Additionally, functional class between young men and women did not differ which 
might refl ect why re-admission rates for HF did not differ either(125, 126). Moreover, 
there was no difference in mortality rates between sexes. 
Patients <55 years vs. controls 
Compared to controls from the general population patients <55 years had higher oc-
currence of all coexisting conditions. The mortality rates were also signifi cantly high-
er in patients, both men and women. 
Strikingly, the highest relative mortality risk was among the youngest patients 18-34 
years of age, which was up to 38 times higher than in controls. There might be a few 
explanations for that. First, there were more with HFmrEF and HFpEF among the 
youngest patients, and consequently lacking the indication for lifesaving treatment. 
Second, having comorbid cancer increased the mortality risk at most, up to three times 
in patients 18-34 years of age. Third, the lowest mortality rates were found among the 
youngest controls, resulting in the highest risk ratio for mortality. 
In absolute numbers, mortality rates did not differ among sexes, but when compared 
to controls from the general population relative mortality risks were almost doubled 
in women than in men <55 years with HF but this difference was not signifi cant and 
thereby congruent with previous data on patients with HF(91). Female controls had 
lower mortality rates, thereby the HR for all-cause mortality were higher. 
Moreover, when addressing prognosis comorbidities play an important role(127, 128). 
Coexisting cancer and kidney disease at baseline were associated with increased mor-
tality risk in both men and women. Furthermore, more young women died of non-
cardiovascular causes compared to men. Cancer was registered as underlying cause 
of death in 22.2% of women and 9.1% of men. 
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The mortality risk was highest among the youngest patients and decreased with age, 
as was the case with life-years lost. The youngest patients lost up to 26 years when 
compared to the conditional life expectancy of controls. According the estimated life 
expectancy in the general population, women are likely to live longer than men. In 
this cohort of patient with HF <55 years at the age of 30 years men and women lost 
approximately as many life-years.  After the age of 30, women lost more life-years 
than young men with HF. 
Strengths and limitations
In Paper I high validity of the cardiomyopathy diagnoses was found in an unselected 
population which included a review of 611 medical records of patients covering large 
parts of western Sweden. To our knowledge this is the fi rst study to assess the validity 
of cardiomyopathy diagnoses. The study population was recruited from three different 
types of hospital and the use of echocardiography was constantly high over the whole 
study period. Even so, in a few instances complete echocardiography reports could 
not be found. 
All records were analyzed by an experienced investigator. In doubtful cases two car-
diologists separately investigated the cases. Moreover, 20 randomly selected medical 
records were independently evaluated by two cardiologists and with 100% confor-
mity. In the early years 1989 to 1990 we only found a few cases of cardiomyopathy 
diagnoses, which remains unexplained but might hypothetically refl ect a real increase 
of the cardiomyopathy diagnoses, something which has been shown previously in 
studies from our group(17).
In Paper II, where a nationwide register with almost complete coverage throughout 
Sweden was used, a high number of patients and controls over a long time period 
were included. A previous study confi rmed high validity of the HF diagnosis in the 
NPR and the external validation of the NPR also showed high validity for other 
diagnoses including heart disease(94, 95). Underreporting hypertension was prob-
ably present but it is unlikely to infl uence mortality rates differently in different 
age groups. Also, data about time and cause of death was taken from the Cause of 
Death Register with a practically complete coverage(96). However, data on eg. cardiac 
biomarkers such as TNT or NT-proBNP as well as data on EF would have added 
value to this study.  
In Paper III and IV the description of young patients with HF were based on a more 
contemporary cohort when compared to other studies. Besides, this study presents 
a comprehensive evaluation from a more unselected patient population than earlier 
studies(43, 54, 55, 99) including patients within the whole range of EF, description of men 
and women separately and corresponding comparison with the general population. 
Furthermore, to our knowledge the estimation of life-years lost has not been per-
formed previously in patients with HF. The population studied was selected from 
SwedeHF, a national quality register that includes a large number of patients through-
out Sweden. The prevalence of cardiomyopathy in this cohort corresponded well to 
that of a previously published nationwide study on all hospitalized patients in Sweden 
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further confi rming the representativity of the cohort(17). However, involvement by hos-
pitals and primary care clinics in the SwedeHF is optional and selection bias is thereby 
a potential limitation. Variables with incomplete data were excluded from statistical 
analysis and reduced the opportunity to use the register to its full potential. Due to the 
small number of patients with congenital heart disease specifi c subgroups were not 
analysed and data should be interpreted with caution. Also, specifi c forms of cancer 
were not studied which should be kept in mind when interpreting the results of the 
impact of cancer at baseline on mortality. 
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CONCLUSIONS
Paper I of this doctoral thesis reports high validity of the cardiomyopathy diagnoses 
and supports the hypothesis that a real increase of the disease might have taken place. 
Paper II of this thesis demonstrates decreasing trends in mortality over time, mainly 
among patients with HF <65 years, while the mortality trends in patients aged 65 
years improved only slightly. Mortality rates decreased even more in the general pop-
ulation. Consequently, both short- and long- term relative risk for all-cause mortality 
increased in patients, particularly in the younger age group.  
Paper III and IV showed that young patients with HF had different characteristics than 
elderly and compared with the general population they had higher occurrence of all 
comorbidities. Patients <55 years had lower mortality rates and better survival com-
pared to older patients but when compared with the age matched controls the relative 
mortality rates, mortality risk and life-years lost were markedly higher, this was espe-
cially obvious among the youngest patients. At the age of 30 years patients may lose 
up to 31.6% of the expected life time. The mortality risk and life-years lost decreased 
with increasing age. After the age of 30, women lost more life-years than men, as they 
were expected to live longer. Baseline comorbidities were of importance, while they 
had impact on the survival, especially cancer. Modifi able coexisting conditions should 
be recognized. Specifi c programs may be needed if presence of comorbidities, such as 
cancer, in young age to further optimize management and improve survival.  
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CLINICAL IMPLICATIONS
This project is well established clinically. Why the HF diagnosis is increasing among 
young patients is unclear and important to investigate due to its high morbidity and 
mortality. There is always an underlying cause to HF, and in this thesis, we primar-
ily wanted to seek the causes of the increase in HF by studying co-morbidities. The 
almost three times increase of cardiomyopathy in young adults is extremely worrying. 
The different types of cardiomyopathies have different treatment strategies and dif-
ferent prognosis. Some types may also be prevented. In order to ensure that there is a 
real increase in the diagnosis, it is important to validate the diagnosis. The fi rst Paper 
of this thesis confi rms high validity of the cardiomyopathy diagnoses and supports the 
hypothesis that a real increase might have occurred. Thus, it is extremely important 
to gain more knowledge about the disease and the risks of developing it. Recently, 
an association between obesity and cardiomyopathy has been presented. As obesity 
is increasing in all age groups other etiological links are possible, for example sleep 
apnoea.
Knowledge about aetiology, patient characteristics and prognosis is needed for re-
source allocation in order to prevent modifi able factors, but also for direct treatment 
strategies, to relieving symptoms and improve prognosis for patients with established 
HF. As patients with HF in younger age are a growing patient group it is presumable 
they will have a high health care consumption. As shown in Paper II of this thesis, 
mortality improved only marginally since the beginning of the 21st century in pa-
tients 65 years. This group represents the majority of patients with HF. Also, even 
though the mortality rates decreased in patients <65 years the mortality risk increased 
when compared to age matched counterparts. This suggests that better understand-
ing of etiological factors, co-morbidities, treatment strategies and causes of death are 
thereby needed.  
In Paper III and IV of this thesis we showed that young patients with HF have differ-
ent coexisting conditions than the elderly. The distribution of those conditions differs 
among sexes. This knowledge is important as identifying and treating these condi-
tions may have an impact on prognosis, eg. cancer, and special follow up programs 
may be needed in order to improve prognosis. The mortality risk was up to fi ve times 
higher in the patients and it was almost double as high in women as in men. Besides, 
the impact on life longevity was also greater the younger the patients were when they 
got the HF diagnosis. By estimating mortality risks in patients compared with age and 
sex matched counterparts we are able to give patients more appropriate risk evalua-
tion that may be more accurate than if compared with patients much older and with 
multiple co-morbidities. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA
Bakgrund: Syndromet hjärtsvikt uppstår då hjärtmuskeln inte kan uppfylla kroppens 
metabola krav. Tidigare arbete visade att både hospitaliseringar och förekomsten av 
diagnosen hjärtsvikt ökat bland unga patienter liksom kardiomyopati diagnoserna. 
Nyligen publicerade studier visade att mortaliteten hos patienter med hjärtsvikt fort-
farande är hög.
Syfte: Validera kardiomyopatidiagnoserna i Västra Götaland. Undersöka mortalitets-
trender och risker för död över tid i olika åldersgrupper. Beskriva patienter <55 år 
avseende patientkarakteristika, utfall och mortalitetsrisker med detaljerad beskrivning 
av könsskillnader.
Metoder och Resultat: I delarbete I validerades kardiomyopatidiagnoserna i Västra 
Götaland genom granskning av medicinska journaler på tre sjukhus från 1989 till 
2009. Validiteten av diagnoserna var hög (86%) liksom användning av ultraljud som 
undersöknings metod (99.7%). I delarbete II användes patientregistret, dödsorsaksre-
gistret och populationsregistret. Vi fann överlag sjunkande mortalitet mellan tidspe-
rioder 1987-2002 och 2003-2014, framförallt bland patienter <65år medan förbätt-
ringen hos äldre var minimal. Mortalitetsrisken ökade framförallt hos patienter <65 år 
i samma tidsperioder. I delarbete III och IV har vi använt data från Rikssviktsregistret 
samt samma register som i delarbete II. Patienter <55 år hade högre förekomst av all 
samsjuklighet och dödlighet jämfört med kontroller. Obesitas, kardiomyopatier och 
kongenital hjärtsjukdom var vanligare hos patienter <55 år. Den högsta mortalitets-
risken hittades hos de allra yngsta patienterna som också förlorade fl est levnadsår. 
Medianöverlevnaden vid till exempel 30 år var 56.3 år jämfört med kontrollernas 82.4 
år vilket ger 26.1 förlorade levnadsår. Med åldern minskade mortalitetsrisken och de 
förlorade levnadsåren. Mortalitetsrisken hos patienterna jämfört med kontrollerna var 
nästan dubbelt så hög hos unga kvinnor som hos män. Förväntad livslängd hos kvin-
nor är högre än hos män varför kvinnor förlorade fl er levnadsår än män. Komorbidite-
ter, speciellt cancer, var associerad med ökad mortalitetsrisk hos båda könen. 
Slutsatser: Vi fann hög validitet av kardiomyopatidiagnoserna, vilket stödjer hypote-
sen att ökning av sjukdomen möjligen har skett. Mortaliteten hos patienter med hjärt-
svikt har förbättrats framförallt hos patienter <65 år, medan hos patienter som är äldre 
är förbättringen marginell. Jämfört med kontroller ses en ökning av mortalitetsrisken 
över tid, mest uttalad hos de yngsta patienterna. De allra yngsta patienterna hade högst 
mortalitetsrisk och förlorade levnadsår upp till 26 år i median, båda minskande med 
ökande ålder. Kvinnor med hjärtsvikt <55 år hade dubbel så hög mortalitetsrisk som 
män även om skillnaden inte var signifi kant.
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